blood

Red blood cells
#blood #FDA #Grifols

FDA approves label expansion to treat blood-clotting disorder 

The US Food and Drug Administration (FDA) has approved an expanded indication for Thrombate III, the Grifols-developed drug treating a rare blood-clotting disorder.  Thrombate III is used to prevent hereditary antithrombin deficiency (hATd), becoming the only antithrombin concentrate (ATc) to be approved in both adult and paediatric patients.  The decision by the FDA follows the… Read More

#News #Regulatory

Blood samples in lab
#blood #Clinical trial #Fc-Fusion proteins #Proteins #Rare disease #Thrombotic diseases

First patients dosed in thrombolytic drug trial

TargED Biopharmaceuticals, a biotechnology company focused on developing improved treatments for thrombotic diseases, has dosed the first participant with TGD001. TGD001 is a thrombolytic designed to break down clots of all sizes and compositions – from large clots which cause AIS, down to ‘micro-clots’ which cause conditions such as the… Read More

#News

Patient using blood pressure monitor
#Alnylam Pharmaceuticals #blood #Cardiovascular disease #Hypertension #Phase I trial #RNA

Positive Phase I results for RNAi therapeutic in hypertension

Alnylam Pharmaceuticals has revealed results from its Phase I study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension. The results are published in the New England Journal of Medicine (NEJM). The key data showed that… Read More

#News

Blood cells
#blood #Haematology #Phase III trial #Takeda #Trial data

Promising new drug for chronic blood clotting disorder

Takeda has revealed favourable interim results from its Phase III crossover trial evaluating the safety and efficacy of TAK-755 (recombinant ADAMTS13) replacement therapy for the prophylactic treatment of congenital thrombotic thrombocytopenic purpura (cTTP). cTTP is an ultra-rare, chronic and debilitating blood clotting disorder caused by a… Read More

#News